$MOH

Bernstein reiterated an Outperform rating and $266 price target for Molina Healthcare (MOH) after strong Q3 2026 earnings. MOH reported adjusted EPS of $0.89, beating estimates by 13%, with premium revenues at $10.46B and total revenues at $11.08B. The company raised its full-year Medicaid cost trend expectation to 5.5%. Analysts from Mizuho and Jefferies also reiterated positive ratings, while Cantor Fitzgerald maintained a Neutral rating.

MOH reported Q3 revenue of $11.08B, beating estimates, with adjusted EPS of $0.89, also above expectations. Management maintained full-year EPS guidance. Medicaid margins stabilized due to rate increases, but membership declined. The company launched a $6B Florida CMS contract, expecting initial losses before break-even. Medicare duals performed well, while Marketplace business is being reduced.

Molina Healthcare (MOH) will end its traditional Medicare Advantage drug plans by 2026, affecting about 72,000 members in California, Connecticut, and Illinois. The company recorded a $93 million impairment and expects a $1.00 per share loss from the exit, which aligns with its strategic shift. Affected members must choose new coverage by December 7 during open enrollment to avoid gaps in drug coverage.

Jefferies raised its price target for Molina Healthcare (NYSE:MOH) to $220 from $205, maintaining a Hold rating. The stock trades near $216.64, with InvestingPro valuing it at $271.91. Jefferies cited 2027 rate data, including a 7% average premium increase. Q3 results missed Medicaid expectations but met Medicare and Exchange targets. Molina's Q3 earnings and revenue beat estimates, but guidance remained unchanged. Cantor Fitzgerald reiterated a Neutral rating with a $209 target.

Molina Healthcare Inc's average price target increased from $212.47 to $213.94, with estimates ranging from $147 to $266 per share, according to 17 analysts. This implies a 1% downside from the Oct. 22 closing price. The consensus rating remains 'Hold' among 22 analysts.

MOLINA HEALTHCARE, INC. (MOH) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release Investor Contact: Jeffrey Geyer, Jeffrey.Geyer@molinahealthcare.com , 305-317-3012 Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com , 562-542-1845 Molina Healthcare Reports Third Quarter 2026 Financial Results Reaffirms Full Year 2026 Earnings G

Molina Healthcare reported a 53% drop in adjusted profit per share for Q3 2026, with GAAP EPS at $0.73 and adjusted EPS at $0.89. The company reaffirmed its 2026 guidance, expecting premium revenue of $42 billion and adjusted earnings of at least $5.25 per share. Molina served 4.9 million members as of September 30, 2026, with premium revenue of $10.5 billion for the quarter. The company's medical care ratio was 92.9% for Q3 2026, in line with expectations.

Molina Healthcare (MOH) reports Q3 earnings Wednesday. Last quarter, revenue met expectations at $10.87B, down 4.8% YoY, with a loss of 108K customers. Analysts expect a 5.3% YoY revenue decline this quarter. MOH stock is up 6.3% over the last month, with an average price target of $209.12. UnitedHealth, a peer, recently beat revenue estimates and saw a 4.5% stock increase.

Argus raised its target price for Tenet Healthcare (THC) to $294.00. The company operates 47 hospitals and over 500 outpatient facilities in the US, mainly in the South. This update may impact investor sentiment and trading activity for THC.

Molina Healthcare (MOH) stock rose 3.8% to $212.09 on pre-earnings optimism and positive sector developments. The company's Q3 2026 earnings are due October 21. The Centers for Medicare & Medicaid Services released 2027 Medicare Advantage Star Ratings, benefiting the sector. Molina also secured new contracts in Illinois and Florida, with the latter expected to generate $6 billion in annual premiums. The broader market slipped slightly.